Literature DB >> 22971587

Coinfection with Staphylococcus aureus increases risk of severe coagulopathy in critically ill children with influenza A (H1N1) virus infection.

Trung Nguyen1, Ursula G Kyle, Nancy Jaimon, M Hossein Tcharmtchi, Jorge A Coss-Bu, Fong Lam, Jun Teruya, Laura Loftis.   

Abstract

OBJECTIVES: H1N1 influenza with coinfections has been implicated to have high morbidity and mortality. We hypothesized that critically ill children with 2009 H1N1 and coinfections are at a higher risk of developing disseminated intravascular coagulation.
DESIGN: The chart review included demographics, length-of-stay, severity of illness score (Pediatric Risk of Mortality III acute physiology score), clinical laboratories, and outcomes at hospital day 90 data. Patients were classified as having methicillin-sensitive or -resistant Staphylococcus aureus, other, or no coinfections.
SETTING: Single-center pediatric intensive care unit. PATIENTS: Sixty-six consecutive patients with 2009 H1N1 and influenza A infection.
INTERVENTIONS: None. MAIN
RESULTS: : There were 12, 22, and 32 patients with methicillin-sensitive or -resistant Staphylococcus aureus, other, and no coinfections, respectively. Pediatric critical care unit length-of-stay was 11, 10, and 5.5 days (median), and survival at day 90 was 83%, 96%, and 91% in patients with methicillin-sensitive or -resistant Staphylococcus aureus, other, and no coinfections. Patients with methicillin-sensitive or -resistant Staphylococcus aureus coinfections compared to patients with other, and no coinfections had higher Pediatric Risk of Mortality III acute physiology scores (14 [6-25] vs. 7 [2-10], p = .052 and 6 [2.5-10], p = .008; median [interquartile range]), higher D-dimer (16.1 [7.9-19.3] vs. 1.6 [1.1-4], p = .02 and 2.3 [0.8-8.7] µg/mL, p = .05), longer prothrombin time (19.3 [15.4-25.9] vs. 15.3 [14.8-17.1], p = .04 and 16.6 [14.7-20.4] secs, p < .39) at admission, and lower day-7 platelet counts (90K [26-161K] vs. 277K [98-314], p = .03 and 256K [152-339]/mm, p < .07). Patients with methicillin-sensitive or -resistant Staphylococcus aureus coinfections compared to patients without coinfections were more likely to be sicker with Pediatric Risk of Mortality III acute physiology score >10 vs. <10 (relative risk 2.4; 95% confidence interval 1.2-4.7; p = .035) and have overt disseminated intravascular coagulation (relative risk 4.4; 95% confidence interval 1.3-15.8, p = .025).
CONCLUSIONS: During the 2009-2010 H1N1 pandemic, pediatric patients with influenza A and methicillin-sensitive or -resistant Staphylococcus aureus coinfections were sicker and more likely to develop disseminated intravascular coagulation than patients with other or no coinfections.

Entities:  

Mesh:

Year:  2012        PMID: 22971587      PMCID: PMC3502679          DOI: 10.1097/CCM.0b013e318260c7f8

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  30 in total

Review 1.  Disseminated intravascular coagulation.

Authors:  M Levi; H Ten Cate
Journal:  N Engl J Med       Date:  1999-08-19       Impact factor: 91.245

2.  Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation.

Authors:  F B Taylor; C H Toh; W K Hoots; H Wada; M Levi
Journal:  Thromb Haemost       Date:  2001-11       Impact factor: 5.249

3.  Neutrophil extracellular traps kill bacteria.

Authors:  Volker Brinkmann; Ulrike Reichard; Christian Goosmann; Beatrix Fauler; Yvonne Uhlemann; David S Weiss; Yvette Weinrauch; Arturo Zychlinsky
Journal:  Science       Date:  2004-03-05       Impact factor: 47.728

Review 4.  Current understanding of disseminated intravascular coagulation.

Authors:  Marcel Levi
Journal:  Br J Haematol       Date:  2004-03       Impact factor: 6.998

5.  Critically ill children during the 2009-2010 influenza pandemic in the United States.

Authors:  Adrienne G Randolph; Frances Vaughn; Ryan Sullivan; Lewis Rubinson; B Taylor Thompson; Grace Yoon; Elizabeth Smoot; Todd W Rice; Laura L Loftis; Mark Helfaer; Allan Doctor; Matthew Paden; Heidi Flori; Christopher Babbitt; Ana Lia Graciano; Rainer Gedeit; Ronald C Sanders; John S Giuliano; Jerry Zimmerman; Timothy M Uyeki
Journal:  Pediatrics       Date:  2011-11-07       Impact factor: 7.124

6.  Bacterial pneumonia during the Hong Kong influenza epidemic of 1968-1969.

Authors:  S W Schwarzmann; J L Adler; R J Sullivan; W M Marine
Journal:  Arch Intern Med       Date:  1971-06

Review 7.  International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics.

Authors:  Brahm Goldstein; Brett Giroir; Adrienne Randolph
Journal:  Pediatr Crit Care Med       Date:  2005-01       Impact factor: 3.624

8.  PRISM III: an updated Pediatric Risk of Mortality score.

Authors:  M M Pollack; K M Patel; U E Ruttimann
Journal:  Crit Care Med       Date:  1996-05       Impact factor: 7.598

9.  Pulmonary antibacterial defenses during mild and severe influenza virus infection.

Authors:  C L Nickerson; G J Jakab
Journal:  Infect Immun       Date:  1990-09       Impact factor: 3.441

Review 10.  Postinfluenza toxic shock syndrome.

Authors:  G C Prechter; A K Gerhard
Journal:  Chest       Date:  1989-05       Impact factor: 9.410

View more
  19 in total

Review 1.  The immunology of influenza virus-associated bacterial pneumonia.

Authors:  Keven M Robinson; Jay K Kolls; John F Alcorn
Journal:  Curr Opin Immunol       Date:  2015-02-24       Impact factor: 7.486

Review 2.  The co-pathogenesis of influenza viruses with bacteria in the lung.

Authors:  Jonathan A McCullers
Journal:  Nat Rev Microbiol       Date:  2014-03-03       Impact factor: 60.633

3.  Effects of bacterial and viral co-infections of mycoplasma pneumoniae pneumonia in children: analysis report from Beijing Children's Hospital between 2010 and 2014.

Authors:  Qing Song; Bao-Ping Xu; Kun-Ling Shen
Journal:  Int J Clin Exp Med       Date:  2015-09-15

4.  Methicillin-resistant Staphylococcus aureus-induced thrombo-inflammatory response is reduced with timely antibiotic administration.

Authors:  Zechariah Franks; Robert A Campbell; Adriana Vieira de Abreu; Jeffrey T Holloway; James E Marvin; Bjoern F Kraemer; Guy A Zimmerman; Andrew S Weyrich; Matthew T Rondina
Journal:  Thromb Haemost       Date:  2013-01-24       Impact factor: 5.249

5.  Influenza-associated pediatric deaths in the United States, 2004-2012.

Authors:  Karen K Wong; Seema Jain; Lenee Blanton; Rosaline Dhara; Lynnette Brammer; Alicia M Fry; Lyn Finelli
Journal:  Pediatrics       Date:  2013-10-28       Impact factor: 7.124

6.  Therapeutic Plasma Exchange in Children With Thrombocytopenia-Associated Multiple Organ Failure: The Thrombocytopenia-Associated Multiple Organ Failure Network Prospective Experience.

Authors:  James D Fortenberry; Trung Nguyen; Jocelyn R Grunwell; Rajesh K Aneja; Derek Wheeler; Mark Hall; Geoffrey Fleming; Rod Tarrago; Sandra Buttram; Heidi Dalton; Yong Han; Kirk A Easley; Andrea Knezevic; Tian Dai; Matthew Paden; Joseph A Carcillo
Journal:  Crit Care Med       Date:  2019-03       Impact factor: 7.598

Review 7.  The frequency of influenza and bacterial coinfection: a systematic review and meta-analysis.

Authors:  Eili Y Klein; Bradley Monteforte; Alisha Gupta; Wendi Jiang; Larissa May; Yu-Hsiang Hsieh; Andrea Dugas
Journal:  Influenza Other Respir Viruses       Date:  2016-06-24       Impact factor: 4.380

Review 8.  Port d'Entrée for Respiratory Infections - Does the Influenza A Virus Pave the Way for Bacteria?

Authors:  Nikolai Siemens; Sonja Oehmcke-Hecht; Thomas C Mettenleiter; Bernd Kreikemeyer; Peter Valentin-Weigand; Sven Hammerschmidt
Journal:  Front Microbiol       Date:  2017-12-21       Impact factor: 5.640

9.  Trace Levels of Staphylococcal Enterotoxin Bioactivity Are Concealed in a Mucosal Niche during Pulmonary Inflammation.

Authors:  Antoine Ménoret; Julia Svedova; Bharat Behl; Anthony T Vella
Journal:  PLoS One       Date:  2015-10-28       Impact factor: 3.240

10.  Staphylococcus aureus and Influenza A Virus: Partners in Coinfection.

Authors:  Michelle E Mulcahy; Rachel M McLoughlin
Journal:  MBio       Date:  2016-12-13       Impact factor: 7.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.